Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

Boehringer Ingelheim

Status: Completed

Conditions: Lung Diseases, Interstitial

Study type: Observational

Funder types: Industry

Identifiers

NCT05957198

1199-0541

Details and patient eligibility

About

The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.

Enrollment: 114,921 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥2 fibrosing Interstitial Lung Disease (ILD) diagnoses in any position on different dates of service, within 365 days of each other, and in the same continuous enrollment period during the patient identification period. The fibrosing ILD diagnosis date will be defined as the date of the first fibrosing ILD diagnosis. The two fibrosing ILD diagnosis codes can be one of the following combinations:
• 2 fibrosis codes
• 1 fibrosis code & 1 ILD code that requires fibrosis code
• ≥18 years of age as of the fibrosing ILD diagnosis date
• Continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date (pre-ILD baseline period)

Exclusion criteria

• Fibrosing ILD diagnosis in the 12-month pre-ILD baseline period
• Unknown gender, geographic region, or insurance type

Trial design

114,921 participants in 1 patient group

Patients with fibrotic interstitial lung disease (ILD)

Description:

Patients aged ≥18 years with ≥2 fibrosing ILD diagnoses and continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date as recorded in a commercial, Medicaid, or Medicare plan, using existing administrative claims and EHR data in Optum's Market Clarity Integrated Claims + Clinical database for the patient identification period (01-Oct-2016 through 30-Jun-2022).